This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration) |
| B. Synonyms | Factor V deficiency, Labile factor deficiency, AC globulin deficiency, Parahemophilia, Owren disease |
| C. Adult onset | Likelihood of first onset in adulthood: not low — mild deficiency is sometimes first discovered in adulthood through excessive bleeding after surgery·procedures |
| 1. History | Etymology of the name proaccelerin: a history that began with the concept of a 'precursor of accelerin' |
| 2. Causes | Pathogenic variants of the F5 gene (1q24.2); impact of the labile property on pathophysiology |
| 3. Genetics | Domain structure of the FV molecule and genetic contrast between FV deficiency and FV Leiden |
| 4. Epidemiology | Rare bleeding disorder affecting about 1 in 1 million people |
| 5. Pathophysiology | Catalytic cofactor function of FVa, mechanism of inactivation by APC, mechanistic contrast with the FV Leiden variant |
| 6. Symptoms | Mucosal bleeding, menorrhagia, postoperative bleeding, rare joint bleeding |
| 7. Signs | Simultaneous prolongation of PT·APTT, normal TT |
| 8. Screening | Precautions for blood collection and testing considering FV instability during blood storage |
| 9. Diagnosis | FV activity assay, exclusion of labile storage artifacts, F5 gene analysis |
| 10. Treatment | FFP (immediate-use principle), platelet transfusion, tranexamic acid |
| 11. Prognosis | Normal life possible with appropriate treatment; thrombotic risk must be assessed depending on whether FV Leiden coexists |
| 12. Prevention | Preoperative FFP replacement, delivery planning for female patients, genetic counseling |
| 13. References | Asselta R, Peyvandi F (2009) Semin Thromb Hemost … and 11 other papers |
Proaccelerin is a name emphasizing the inactive precursor form of coagulation factor V (FV); the name was first proposed in 1947 by Paul Owren of Norway. Owren hypothesized that FV circulates in plasma in an inactive precursor (pro-) form and is converted to an active form (-accelerin) by coagulation stimuli. That is, 'Proaccelerin' carries the meaning of 'precursor of the accelerating factor (accelerin)', expressing the inactive zymogen state of FV before activation.
This name is also related to the biochemical properties of FV, particularly its lability. Proaccelerin is barely detectable in serum because it is consumed or degraded during coagulation. Even in refrigerated blood, FV (proaccelerin) rapidly loses activity, earning it the nickname 'labile factor'. This labile property is also important in clinical testing: if testing is not performed promptly after blood collection, false-negative results may be obtained.
When the International Committee for the Nomenclature of Blood Clotting Factors introduced the Roman numeral system in 1960, proaccelerin (the precursor form of FV) and accelerin (FVa, the activated form) were unified and came to be called Factor V (coagulation factor V, FV). However, in the academic literature, the notation 'proaccelerin' is still used for the inactive form and 'FVa (factor Va)' for the activated form. In the ICD codes, 'Proaccelerin deficiency' is listed as an inclusion term of D68.2, so this historical name still lives on within the official coding system.
In 1993–1994, when the research groups of Dahlbäck et al. and Bertina et al. respectively described the phenomenon of activated protein C (APC) resistance and its cause, the FV Leiden variant (p.Arg534Gln), research on FV (proaccelerin) entered a new phase. In FV Leiden, a variant at the site of FVa inactivation by APC (Arg534) causes FVa to remain excessively active, inducing a thrombotic tendency. This discovery made clear that FV deficiency (bleeding) and FV Leiden (thrombosis) are different aspects of the same molecule, and redefined FV as a central molecule in the balance of coagulation and anticoagulation.
Proaccelerin (FV) is converted to FVa by activated FXa and thrombin during coagulation. In the inactive FV (proaccelerin) state, the large B domain lies between the A2 and A3 domains and blocks the active site. Cleavage of the B domain by thrombin or FXa generates FVa, and this process is rapid and irreversible. Proaccelerin is not detected in serum because it is entirely consumed during coagulation or degraded by APC and others.
The cause of proaccelerin deficiency (FV deficiency) is variants of the F5 gene (1q24.2), the same molecular basis as AC globulin deficiency. However, what this file emphasizes is the molecular structure of FV and the dynamics of activation-inactivation. Importantly, FV deficiency can be divided into cases limited simply to a reduction in protein quantity (type 1) and cases in which protein quantity is normal but function is impaired (type 2, dysfunctional). Unlike the historical·nomenclature aspects covered in the AC globulin deficiency document, the molecular mechanism aspects are covered here in more depth.
Proaccelerin (FV) has high structural similarity to coagulation factor FVIII (antihemophilic factor A). Both factors share the A1-A2-B-A3-C1-C2 domain arrangement, and the B domain is removed upon activation. This similarity suggests that the two factors evolved from a common ancestral gene. In addition, the fact that combined deficiency of FV and FVIII (F5F8D) arises because the two factors share an intracellular transport pathway stems from this structural commonality. Understanding this similarity helps in the comparative analysis of the deficiency syndromes of the two factors.
The F5 gene (chromosome 1q24.2) has 25 exons, is about 80 kb in size, and encodes the FV protein of 2,224 amino acids. The key sites of the FV protein in coagulation regulation are the APC cleavage sites, Arg306 (A1 domain) and Arg506 and Arg679 (A2 domain). In particular, Arg506 is the main site of FVa inactivation by APC, and a variant at this site (p.Arg534Gln, old numbering Arg506Gln) causes FV Leiden.
Deficiency variants occur at sites unrelated to these APC cleavage sites and impair FV synthesis or secretion, whereas FV Leiden is a variant precisely at an APC cleavage site that causes hyperactivation of FV. These two types of variants are located at different positions within the F5 gene and share the same gene even though their clinical phenotypes are completely opposite. This contrast is a representative example in coagulation education showing how varied the functional consequences of gene variants can be depending on the location and nature of the variant.
Rarely, a compound heterozygote exists with an FV deficiency-causing variant on one allele and the FV Leiden variant on the other. In this case the plasma FV level is reduced (from the FV deficiency allele), but all remaining FV is the Leiden variant and shows APC resistance. In this interesting genotype, thrombotic tendency may be more prominent than bleeding tendency, and a clinically complex evaluation is required. This case suggests that in patients with FV deficiency, one should not rely only on simple measurement of FV activity but must also perform FV Leiden testing.
Proaccelerin deficiency (FV deficiency) is a rare bleeding disorder with a prevalence of about 1 in 1 million; according to the World Federation of Hemophilia (WFH) Global Survey, registered patients worldwide number in the thousands. This is far rarer than hemophilia A (about 1 in 6,000). It occurs with equal frequency in males and females without sex bias (autosomal recessive inheritance). Clustering is reported in regions where consanguineous marriage is frequent (Iran, Pakistan, some Arab regions).
The FV Leiden variant has a heterozygous prevalence of about 4–6% in European Caucasian populations and is the most common cause of inherited thrombophilia. Compared with the prevalence of FV deficiency (about 1 in 1 million), this is about 40,000–60,000 times more common. The prevalence of FV Leiden homozygotes is about 1/5,000, and the risk of deep vein thrombosis is higher than in heterozygotes. The frequency of FV Leiden in East Asian populations, including Koreans, is very low compared with Europe (less than about 0.1%). This epidemiological contrast shows the stark difference between deficiency (ultra-rare) and gain-of-function variants (common) caused by the same gene.
When proaccelerin (FV) is activated by thrombin or FXa, it becomes FVa (accelerin). In the common pathway of the coagulation cascade, FVa, as a cofactor of the prothrombinase complex, increases the efficiency of prothrombin cleavage by FXa about 10,000-fold. This efficiency gain means that, because FXa alone cannot generate thrombin at a sufficient rate, FVa is essential for physiologically meaningful clot formation. In FV deficiency, the rate of prothrombin cleavage decreases dramatically, resulting in failure of thrombin generation and inability to achieve hemostasis.
Under normal conditions, activated protein C (APC), with protein S as a cofactor, inactivates FVa by cleaving it at Arg306 and Arg506. This process is a key anticoagulant mechanism limiting thrombus formation. In FV Leiden (p.Arg534Gln), the arginine at the Arg506 (old numbering) cleavage site is replaced by glutamine, making cleavage by APC impossible. As a result, FVa Leiden remains active much longer than normal FVa, leading to excessive thrombin generation and thrombus formation.
Understanding this mechanism makes it clear that FV deficiency and FV Leiden represent opposite pathophysiologies of the same molecule. In FV deficiency, FVa is insufficient and thrombin generation is reduced (bleeding tendency); in FV Leiden, FVa is not inactivated and remains hyperactive, causing excessive thrombin generation (thrombotic tendency). The contrast between these two clinical entities is a key teaching point for understanding the molecular basis of hemostatic balance.
Platelet α-granules store a considerable amount of FV. Upon platelet activation, this FV is secreted and binds FXa on the activated platelet surface, forming the prothrombinase complex. Platelet FV may differ partly in structure from plasma FV (some already partially cleaved) and is stored bound to coagulation regulatory proteins (e.g., multimerin). In FV-deficient patients, bleeding tendency is more severe when platelet FV levels are also reduced, whereas bleeding may be mild when platelet FV is relatively preserved.
The bleeding symptoms of proaccelerin deficiency (FV deficiency) arise from the same clinical entity as AC globulin deficiency, but this document focuses on understanding the bleeding phenotype from the perspective of molecular structure and function. The most common bleeding symptom is mucosal bleeding, including nosebleeds, gum bleeding, and oral mucosal bleeding. Gastrointestinal bleeding and hematuria are also reported. Excessive bleeding after surgery, tooth extraction, or trauma often prompts the diagnosis.
In severe FV deficiency (FV activity below 1%), spontaneous joint bleeding rarely occurs, and in such cases the clinical course may resemble hemophilia A. Intracranial hemorrhage is a life-threatening complication, especially in patients with severe deficiency. According to EN-RBD data, intracranial hemorrhage is reported in about 10% of patients with severe FV deficiency.
In female patients with FV deficiency, menorrhagia is one of the most common symptoms, and excessive menstrual bleeding sometimes causes anemia. During pregnancy, FV levels tend to rise physiologically, so bleeding risk may decrease somewhat, but in severe deficiency this physiological increase is insufficient and the risk of massive hemorrhage at delivery persists. A risk of placental abruption due to FV deficiency in the placenta has also been reported. A planned approach through hematology·obstetrics collaboration is essential for pregnancy and delivery.
Because proaccelerin (FV) is located in the common pathway of the coagulation cascade, whether coagulation is initiated by the extrinsic pathway (PT) or the intrinsic pathway (APTT), the defect ultimately occurs in the common pathway passing through FV. Therefore, in FV deficiency both PT and APTT are prolonged. Because FV is not directly involved in fibrinogen conversion, the thrombin time (TT) is normal. FV activity measurement using FV substrate plasma in a one-stage clotting assay is essential for confirmation.
The most important biochemical property of proaccelerin (FV) is its lability. FV in collected blood loses activity within hours at room temperature and within days even when refrigerated. Therefore, after blood is collected for FV activity testing, the test should be performed as quickly as possible. Delayed testing after collection or improper blood storage can cause artifactual FV reduction, giving false-positive findings of deficiency. To prevent this, clinical laboratories follow the principle of separating plasma immediately after collection and either freezing it immediately (-80°C) or testing within 2 hours.
FV is called the 'labile factor' because not only is it consumed during coagulation so that none remains in serum, but it is also easily degraded outside the body. Because of this property, specimen handling has a decisive effect on results when screening for FV deficiency. Specifically, FV activity may be artificially reduced if the time from blood collection to testing is long, if the specimen is left at room temperature for a long time, or if there are repeated freeze-thaw cycles. Therefore, when ordering an FV activity test, the specimen should be centrifuged immediately after collection and the plasma stored at -80°C or below, or the test completed within 2 hours.
When PT and APTT are both prolonged and TT is normal, deficiency of common pathway factors (FV, FX, FII) must be differentiated from acquired combined coagulation abnormalities (vitamin K deficiency, liver disease, anticoagulants). In vitamin K deficiency, FV is normal while FII, FVII, FIX, and FX are reduced simultaneously, so both PT·APTT are prolonged but are corrected by vitamin K administration. In FV deficiency, the important feature is lack of correction after vitamin K administration. Clinical screening using the ISTH BAT (bleeding score) should be performed alongside laboratory screening.
In confirming proaccelerin deficiency (FV deficiency), standardization of specimen handling is the first step. Step 1: centrifugation (2,500g, 15 minutes) immediately after blood collection (3.2% sodium citrate tube). Step 2: aliquot plasma immediately and store at -80°C, or perform the FV activity test within 2 hours. Step 3: one-stage FV clotting activity assay using FV substrate plasma (FV-deficient plasma). Step 4: mixing study to exclude factor-specific inhibitors. Step 5: FV antigen measurement (to distinguish qualitative vs. quantitative deficiency). Step 6: confirm the pathogenic variant by F5 gene analysis.
When diagnosing FV deficiency, it is clinically meaningful to perform FV Leiden testing (PCR or restriction enzyme analysis) concurrently to exclude the possible coexistence of the FV Leiden variant in the same patient or family. In particular, in patients with low FV activity but a history of thrombosis, or when thrombotic tendency is suspected in patients with heterozygous FV deficiency, FV Leiden status may determine the direction of treatment (whether to add thromboprophylaxis). The APC resistance test (APTT-based) is used for phenotypic screening of FV Leiden.
In the treatment of proaccelerin deficiency, Fresh Frozen Plasma (FFP) is currently the only licensed product that can supply FV. FFP is plasma frozen within 6 hours of collection, in which all coagulation factors including FV are preserved. Because of the labile property of FV, FFP should be administered as quickly as possible after thawing (ideally within 1–2 hours). If left for a long time after thawing, FV activity may decrease. The dose is generally 15–20 mL/kg, and the target FV level is 15–25% for minor surgery and 25% or higher for major surgery.
To supply the FV stored in platelets, platelet transfusion is recommended in combination with FFP for severe bleeding or major surgery. Platelet transfusion has significance as a direct supply of FV beyond the simple purpose of platelet replacement. Tranexamic acid is adjunctively useful, especially when mucosal bleeding predominates. For control of menorrhagia, oral contraceptives or a levonorgestrel intrauterine system (LNG-IUS) are effective. If an FV-specific concentrate were developed, it would overcome the instability problem and allow more precise dose adjustment, but no such product is currently available for clinical use.
With appropriate FFP treatment, proaccelerin deficiency (FV deficiency) allows normal life expectancy and daily functioning in most patients. In mild deficiency (FV >10%), there are no restrictions on daily activities, and bleeding is prevented by prophylactic FFP during surgery·trauma. In severe deficiency, intracranial hemorrhage occurring without prophylactic treatment can lead to permanent neurological damage or death, in which case the prognosis is poor. Transfusion-related adverse effects of FFP administration (viral infection, alloimmunization), when they occur, may affect long-term prognosis.
When FV Leiden coexists in a patient with FV deficiency, all remaining FV is the APC-resistant variant, so thrombotic risk may be more prominent than bleeding risk. In this compound heterozygous state, the need for anticoagulant treatment must be considered together with treatment of bleeding, and a tailored approach according to the individual patient's clinical situation is required. Even in patients with pure FV deficiency, thrombotic risk assessment is needed when thrombogenic situations such as hospitalization, surgery, or immobilization arise during long-term FFP treatment.
In patients with proaccelerin deficiency, FFP is prepared before planned surgery and administered just before surgery (preferably within 1–2 hours). To preserve the FV activity of FFP, immediate use after thawing is the rule. Target FV levels are set according to the type of surgery, and FV activity is monitored before and after surgery. For major surgery, additional FFP administration may be needed for several days after surgery. For tooth extraction or minor procedures, FFP administration can be reduced by using tranexamic acid and local hemostatic agents.
Genetic counseling and carrier testing are recommended for the parents, siblings, and children of patients with proaccelerin deficiency. Particularly in patients of European ancestry, checking for the coexisting FV Leiden variant is clinically important. In heterozygous carriers, the possibility that FV levels will fall below the critical threshold during surgery·trauma·pregnancy is assessed and a prevention plan is established. Female FV-deficient patients planning pregnancy need a multidisciplinary plan including delivery planning, peripartum monitoring, and immediate coagulation testing of the newborn.